Month: December 2025

ISG to Evaluate Snowflake Ecosystem Partners

Posted on by slightbourne@noblecapitalmarkets.com

12/2/2025

STAMFORD, Conn.–(BUSINESS WIRE)– Information Services Group (ISG) (Nasdaq: III), a global AI-centered technology research and advisory firm, has launched a research study examining provider capabilities within the fast-growing Snowflake services ecosystem.

The study results will be published in a comprehensive ISG Provider Lens® report, called Snowflake Ecosystem Partners, scheduled to be released in June 2026. The report will cover companies offering Snowflake-focused modernization and AI and ML enablement capabilities, along with ongoing managed data and optimization services.

Enterprise buyers will be able to use information from the report to evaluate their current vendor relationships, potential new engagements and available offerings, while ISG advisors use the information to recommend providers to the firm’s buy-side clients.

Snowflake has emerged as a critical data platform that redefines how enterprises store, process and activate data for analytics and AI. Its cloud-native architecture offers improved scalability, flexibility and cost efficiency, helping enterprises move beyond the constraints of traditional data warehouses. Globally, enterprises are increasingly adopting this platform to unify structured, semi-structured and unstructured data under a single governance and security model. This approach streamlines complex data operations while enabling faster insights and AI-driven innovation.

“Enterprises are prioritizing providers that offer automation maturity, FinOps discipline and robust governance,” said Aman Munglani, senior director and principal analyst at ISG. “Using Snowflake-native tools such as Snowpark, Cortex AI and Native Apps enables them to achieve meaningful, measurable improvements in data management.”

ISG has distributed surveys to more than 100 Snowflake ecosystem partners. Working in collaboration with ISG’s global advisors, the research team will produce two quadrants representing the Snowflake offerings the typical enterprise is buying, based on ISG’s experience working with its clients. The two quadrants are:

  • Modernization and AI/ML Enablement Services, evaluating providers that deliver end-to-end strategy, advisory and implementation support to help enterprises get the most from their Snowflake investments. These providers are assessed on their ability to guide data modernization efforts and facilitate integration of AI and ML into operations.
  • Managed Data and Optimization Services,assessing providers offering management, monitoring and optimization services for Snowflake environments. These providers should specialize in managing Snowflake infrastructure across cloud platforms and offer training and change management initiatives.

Geographically focused reports from the study will cover the global Snowflake ecosystem and examine products and services available worldwide. ISG analysts Gowtham Kumar Sampath and Hemangi Patel will serve as authors of the report.

A list of identified providers and vendors and further details on the study are available in this digital brochure. Companies not listed as Snowflake ecosystem partners can contact ISG and ask to be included in the study.

All 2025 ISG Provider Lens® evaluations feature expanded customer experience (CX) data that measures actual enterprise experience with specific provider services and solutions, based on ISG’s continuous CX research.

About ISG Provider Lens® Research

The ISG Provider Lens® Quadrant research series is the only service provider evaluation of its kind to combine empirical, data-driven research and market analysis with the real-world experience and observations of ISG’s global advisory team. Enterprises will find a wealth of detailed data and market analysis to help guide their selection of appropriate sourcing partners, while ISG advisors use the reports to validate their own market knowledge and make recommendations to ISG’s enterprise clients. The research currently covers providers offering their services globally, across Europe, as well as in the U.S., Canada, Mexico, Brazil, the U.K., France, Benelux, Germany, Switzerland, the Nordics, Australia and Singapore/Malaysia, with additional markets to be added in the future. For more information about ISG Provider Lens research, please visit this webpage.

About ISG

ISG (Nasdaq: III) is a global AI-centered technology research and advisory firm. A trusted partner to more than 900 clients, including 75 of the world’s top 100 enterprises, ISG is a long-time leader in technology and business services that is now at the forefront of leveraging AI to help organizations achieve operational excellence and faster growth. The firm, founded in 2006, is known for its proprietary market data, in-depth knowledge of provider ecosystems, and the expertise of its 1,600 professionals worldwide working together to help clients maximize the value of their technology investments.

Source: Information Services Group, Inc.

Mistral Unveils New AI Models as Europe’s Rising Lab Races to Keep Pace with OpenAI and Google

Posted on by slightbourne@noblecapitalmarkets.com

French artificial intelligence startup Mistral has introduced a new suite of advanced AI models, marking its most ambitious step yet as it races to remain competitive with global heavyweights like OpenAI, Google, and DeepSeek. The release comes at a pivotal moment in the AI ecosystem, where rapid innovation cycles and aggressive commercialization strategies are reshaping the landscape.

Mistral’s updated portfolio includes a new large multimodal model, which the company describes as the “world’s best open-weight multimodal and multilingual.” Designed for enterprise-grade performance, this model targets use cases such as AI assistants, scientific workloads, retrieval-augmented generation (RAG) systems, and complex agentic workflows. By pushing for open-weight access, Mistral continues to position itself as a key proponent of transparent and customizable AI—an increasingly important stance among European enterprises wary of closed-source dominance from U.S. labs.

Alongside the flagship model, the company launched Ministral 3, a compact, highly efficient model engineered for robotics, autonomous drones, consumer devices, and on-device intelligence. Its smaller footprint allows it to run on a single GPU, reducing operational costs and making it attractive for companies seeking scalable, low-latency AI without heavy cloud dependency. According to Mistral, smaller models offer major advantages in real-world applications, where speed, cost efficiency, and domain-specific tuning outperform size alone.

The launches build on a year of rapid growth for the Paris-based startup. Founded in 2023, Mistral raised 1.7 billion euros in September, reaching a valuation of 11.7 billion euros. The round was led by global semiconductor leader ASML, which invested 1.3 billion euros, with additional backing from Nvidia, Microsoft, and Andreessen Horowitz. This massive inflow of capital reflects Europe’s mounting urgency to develop AI champions capable of competing with U.S. and Chinese giants.

Mistral’s momentum extends beyond research. On Monday, the company announced a major commercial agreement with HSBC, granting the global bank access to its models for tasks such as financial forecasting, language translation, and automation. The startup has already secured additional enterprise contracts worth hundreds of millions of dollars, signaling growing trust from large organizations seeking alternatives to entrenched U.S. players.

Still, the competitive backdrop is intense. Rivals such as Anthropic and OpenAI are aggressively expanding into Europe, opening new offices and securing colossal funding rounds that dwarf those of European firms. With Anthropic now valued at $183 billion and OpenAI reportedly priced at nearly $500 billion through secondary sales, Mistral faces an uphill battle to match the scale of global rivals.

Nonetheless, the company maintains that the next era of AI will be defined not only by size, but by speed, adaptability, on-device intelligence, and openness. With its new models, Mistral aims to position itself at the forefront of this shift—advancing its vision of a globally distributed AI ecosystem that blends cutting-edge research with practical enterprise deployment.

Amazon Unveils New Trainium3 AI Chip as Big Tech Ramps Up Efforts to Challenge Nvidia’s Dominance

Posted on by slightbourne@noblecapitalmarkets.com

Amazon has introduced its newest AI semiconductor, Trainium3, signaling another major push by tech giants to loosen Nvidia’s grip on the rapidly growing artificial intelligence hardware market. Announced Tuesday during Amazon Web Services’ annual re:Invent conference, the chip represents a significant leap in the company’s strategy to build affordable, high-performance computing infrastructure tailored for AI training and inference.

According to AWS, servers outfitted with Trainium3 deliver four times the speed and energy efficiency of the previous generation. For enterprises racing to scale large language models and multimodal systems, this improvement translates to faster development cycles and noticeably lower operational costs—an increasingly critical advantage as AI workloads explode.

“Trainium already represents a multibillion-dollar business today and continues to grow really rapidly,” said AWS CEO Matt Garman, underscoring Amazon’s deepening investment in custom silicon. Once primarily dependent on Nvidia for its cloud AI capacity, AWS now sees homegrown hardware as essential both for performance control and long-term cost stability.

Amazon is far from alone. The industry has entered a new era in which Nvidia’s largest customers—Google, Microsoft, Meta, and Amazon itself—are designing their own AI chips to reduce reliance on the GPU leader. In early November, Google debuted its Ironwood TPU v7, and reports suggest the company is negotiating a multibillion-dollar deal to supply TPUs to Meta. Meanwhile, Microsoft continues to develop its in-house silicon despite encountering delays.

AWS executives view this diversification as healthy for the broader ecosystem. “Diversity of chips in the AI market is a good thing,” said Dave Brown, AWS vice president of compute and machine learning, in an interview with Yahoo Finance. Brown emphasized that the rising demand for AI infrastructure is creating room for multiple architectures to coexist, each optimized for different workloads.

Cost remains one of Amazon’s sharpest competitive angles. Brown noted that developers using Trainium-based instances typically see 30% to 40% savings compared to Nvidia GPU clusters. At a time when AI model training can reach hundreds of millions—or even billions—of dollars, these savings could shift market dynamics.

Amazon is also expanding its AI infrastructure at massive scale. The company recently completed Project Rainier, a colossal data center initiative built specifically for AI workloads. OpenAI competitor Anthropic is expected to use one million of Amazon’s custom chips across Rainier and other AWS data centers by the end of 2025. Anthropic has reportedly played a hands-on role in guiding the chip’s design.

Still, Nvidia remains unmatched in both raw performance and software ecosystem maturity. CEO Jensen Huang has argued that developers would choose Nvidia chips “even if alternatives were free,” citing CUDA and the extensive tools built around Nvidia hardware. Amazon itself remains one of Nvidia’s biggest customers, accounting for 7.5% of Nvidia’s revenue, and OpenAI recently signed a $38 billion agreement to access Nvidia GPUs through AWS.

Yet Amazon is preparing for a future where its chips coexist seamlessly with Nvidia’s. The company revealed that its upcoming Trainium4 processors will support NVLink Fusion, Nvidia’s advanced networking technology that links chips across server racks. That compatibility signals a hybrid future—one where Amazon tightens control over its hardware roadmap while still acknowledging Nvidia as the industry’s gold standard.

Release – MAIA Biotechnology Announces Open Market Purchases by CEO and Directors

Posted on by aweinsoff@channelchek.com

Research News and Market Data on MAIA

December 01, 2025 9:17am EST Download as PDF

CHICAGO, Dec. 01, 2025 (GLOBE NEWSWIRE) — MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that the CEO and certain members of the Company’s Board of Directors purchased approximately 182,445 shares of MAIA common stock at market price between November 21 and 28, 2025. The average common stock price was $1.06.

Vlad Vitoc, M.D., Chairman and CEO of MAIA, purchased 94,300 shares between November 21 and 28, 2025, at an average price of $1.08 per share. Other board members, Cristian Luput and Stan V. Smith, Ph.D., purchased a combined total of 88,145 shares in the open market at an average price of $1.04 per share.

“Along with my fellow MAIA Board members, we are pleased to report that we recently acquired shares of MAIA in the open market, reflecting our confidence in ateganosine’s ongoing clinical development,” said Dr. Vitoc. “With 38% response rates and 17.8 months overall survival in our Phase 2 THIO-101 clinical trial to date, we believe in ateganosine’s potential to improve the lives of patients diagnosed with non-small cell lung cancer and become a new standard of care.”

“I firmly believe MAIA’s cancer-therapy platform can redefine the landscape of cancer research and treatment,” said Mr. Luput. “As a longtime investor, I believe the company’s strategic focus and scientific momentum position it to deliver significant value for shareholders in the years ahead,” added Mr. Smith.

About MAIA Biotechnology, Inc.

MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is ateganosine (THIO), a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. For more information, please visit www.maiabiotech.com.

Forward Looking Statements

MAIA cautions that all statements, other than statements of historical facts contained in this press release, are forward-looking statements. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry’s actual results, levels or activity, performance or achievements to be materially different from those anticipated by such statements. The use of words such as “may,” “might,” “will,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expressions are intended to identify forward looking statements. However, the absence of these words does not mean that statements are not forward-looking. For example, all statements we make regarding (i) the initiation, timing, cost, progress and results of our preclinical and clinical studies and our research and development programs, (ii) our ability to advance product candidates into, and successfully complete, clinical studies, (iii) the timing or likelihood of regulatory filings and approvals, (iv) our ability to develop, manufacture and commercialize our product candidates and to improve the manufacturing process, (v) the rate and degree of market acceptance of our product candidates, (vi) the size and growth potential of the markets for our product candidates and our ability to serve those markets, and (vii) our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates, are forward looking. All forward-looking statements are based on current estimates, assumptions and expectations by our management that, although we believe to be reasonable, are inherently uncertain. Any forward-looking statement expressing an expectation or belief as to future events is expressed in good faith and believed to be reasonable at the time such forward-looking statement is made. However, these statements are not guarantees of future events and are subject to risks and uncertainties and other factors beyond our control that may cause actual results to differ materially from those expressed in any forward-looking statement. Any forward-looking statement speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. In this release, unless the context requires otherwise, “MAIA,” “Company,” “we,” “our,” and “us” refers to MAIA Biotechnology, Inc. and its subsidiaries.

Investor Relations Contact
+1 (872) 270-3518
ir@maiabiotech.com

Primary Logo

Source: MAIA Biotechnology, Inc.

Released December 1, 2025

Release – Nicola Mining Commences Receipt Of Blue Lagoon Gold And Silver Millfeed

Posted on by aweinsoff@channelchek.com

December 1, 2025

News Releases

VANCOUVER, BC, December 1, 2025 – Nicola Mining Inc. (the “Company” or “Nicola”) (TSX: NIM) (OTCQB: HUSIF) (FSE: HLIA) is pleased to announce that Blue Lagoon Resources (CSE: BLLG) (“Blue Lagoon”) has commenced transporting high-grade gold and silver millfeed to Nicola’s mill, located near Merritt, British Columbia.  The Company had previously announced[1] that the two parties had entered into a long term partnership[2] and that Nicola, which is also a major Blue Lagoon shareholder, had committed to providing a non-dilutive $2.0 million line of credit to augment the latter’s balance sheet.

Nicola will provide further updates for its 2026 plans in a soon-to-be released Annual Letter to Shareholders, which will include operational insights into milling expansion, Treasure Mountain, Dominion Creek Gold Project and the New Craigmont Project.

Mr. Peter Espig, CEO of Nicola Mining Inc., commented: “We are extremely pleased to see Blue Lagoon achieve this significant milestone as it morphs Dome Mountain Gold Mine from a project to a producing mine.  The two also embrace a shared commitment to sustainability and environmental commitment, as highlighted by Blue Lagoon being the recipient of PDAC’s 2026 Sustainability Award[3].  Nicola’s ability to process materials from multiple sites throughout the Province of British Columbia, including its Treasure Mountain Silver Mine and Dominion Creek Gold Project, highlights our position as a project facilitator of gold and silver projects throughout the province.”

Qualified Person

Cameron Lilly, P. Eng., the Company’s Mill Manager, is the Qualified Person as defined by National Instrument 43-101 – Standards of Disclosure for Mineral Projects and supervised the preparation of, and has reviewed and approved, the technical information in this release.

About Nicola Mining

Nicola Mining Inc. is a junior mining company listed on the Exchange and Frankfurt Exchange that maintains a 100% owned mill and tailings facility, located near Merritt, British Columbia. It has signed Mining and Milling Profit Share Agreements with high grade gold projects.  In addition, it is reviewing the reopening of its Treasure Mountain Silver Mine and will commence production at its Dominion Creek Gold Project in 2026.

Nicola’s fully permitted mill can process both gold and silver mill feed via gravity and flotation processes.

The Company owns 100% of the New Craigmont Project, a high-grade copper property, which covers an area of over 10,800 hectares along the southern end of the Guichon Batholith and is adjacent to Highland Valley Copper, Canada’s largest copper mine. The Company also owns 100% of the Treasure Mountain Property, which includes 30 mineral claims and a mineral lease, spanning an area exceeding 2,200 hectares.

On behalf of the Board of Directors

“Peter Espig”  
Peter Espig
CEO & Director

For additional information

Contact:  Peter Espig
Phone: (778) 385-1213
Email: info@nicolamining.com
URL: www.nicolamining.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

[1] Nicola Mining News Release dated June 23, 2025

[2] Blue Lagoon’s News Release dated September 29, 2025:  Link

[3] News Release:  Link

Release – Cadrenal Therapeutics Appoints Dr. Lee Golden to Board of Directors

Posted on by aweinsoff@channelchek.com

Research News and Market Data on CVKD

PONTE VEDRA, Fla., Dec. 01, 2025 (GLOBE NEWSWIRE) — Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics to overcome current gaps in anticoagulation therapy, today announced the appointment of Lee Scott Golden, M.D., to its Board of Directors, effective immediately. Dr. Golden will serve as an independent director.

Dr. Golden currently serves as Executive Vice President and Chief Medical Officer at PTC Therapeutics, Inc. (Nasdaq: PTCT), where he leads global clinical development across a broad rare disease pipeline. Before joining PTC, Dr. Golden served as the Chief Medical Officer at Espero BioPharma, Inc., a development-stage cardiovascular pharmaceutical company focused on developing drugs for unmet needs in thrombosis and cardiac rhythm control, and as Chief Medical Officer at Gemphire Therapeutics, Inc. He also serves as Chairman of the Advisory Board for Coagulation Sciences LLC. Previously, Dr. Golden held senior roles at Pfizer, Actelion, Eisai, Mesoblast, and others, with a long-standing focus on cardiovascular and hematologic drug development.

“We are delighted to welcome Dr. Golden to our Board,” said Quang X. Pham, Chairman and Chief Executive Officer of Cadrenal Therapeutics. “Lee’s deep experience in late-stage clinical development, particularly in cardiovascular medicine and anticoagulation, is highly aligned with our mission to deliver safer, more predictable anticoagulant options for patients with significant unmet needs. His track record in guiding therapies through clinical development and regulatory pathways will be invaluable as we continue to advance tecarfarin and our broader pipeline.”

“Cadrenal Therapeutics is working in an area of high clinical importance, where better anticoagulation options could meaningfully impact outcomes for patients with complex cardiovascular conditions,” said Dr. Golden. “I look forward to working with the Board and the leadership team to help guide the Company’s strategy and clinical programs as we seek to bring differentiated therapies to patients and create value for shareholders.”

Dr. Golden has more than 25 years of industry experience, with increasing responsibilities, managing global, cross-functional teams responsible for creating and deploying strategic and clinical development plans. He has extensive experience across multiple therapeutic areas and with orphan diseases. Dr. Golden received a B.S. from the University of Michigan and an MD from New York University School of Medicine, where he also completed his Internal Medicine residency. He then completed Fellowships in Cardiology at the University of Miami and Interventional Cardiology at George Washington University Hospital, where he also served as an adjunct instructor.

About Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics, Inc. is a biopharmaceutical company with a mission to develop novel and differentiated biopharmaceutical products that bridge critical gaps in current acute and chronic anticoagulant therapy. We bridge these gaps by developing novel and differentiated anticoagulants, or blood thinners, designed to provide greater predictability, increased stability, more precise control, and fewer bleeding complications. We currently have two clinical-stage assets: tecarfarin, an oral vitamin K antagonist (VKA) for chronic use, and frunexian, a parenteral small-molecule Factor XIa antagonist for use in acute hospital settings. By targeting underserved patient populations and advancing therapies designed for both chronic and acute use, we aim to reshape standards of care in anticoagulation. For more information, visit https://www.cadrenal.com/ and connect with the Company on LinkedIn.

Safe Harbor

Any statements in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements.” The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potentially,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These statements include statements regarding developing transformative therapeutics to overcome current gaps in anticoagulation therapy, the expected contribution of Dr. Golden and continuing to advance tecarfarin and the Company’s broader pipeline. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the ability to develop transformative therapeutics to overcome current gaps in anticoagulation therapy, Dr. Golden’s ability to help guide the Company’s strategy and clinical programs, the ability to successfully complete clinical trials on time and achieve desired results and benefits as expected and the other risk factors described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, and the Company’s subsequent filings with the Securities and Exchange Commission, including subsequent periodic reports on Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Any forward-looking statements contained in this press release speak only as of the date hereof and, except as required by federal securities laws, the Company specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise.

For more information, please contact:

Lytham Partners, LLC
Robert Blum, Managing Partner
602-889-9700
CVKD@lythampartners.com

Release – The Oncology Institute Announces Resignation of Board Member Gabe Ling

Posted on by aweinsoff@channelchek.com

Research News and Market Data on TOI

Dec 01, 2025

PDF Version

CERRITOS, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) — The Oncology Institute, Inc. (“TOI”) (NASDAQ: TOI), one of the largest value-based oncology groups in the United States, today announced that Gabe Ling has resigned from the Board of Directors, effective December 1, 2025. A formal search process has been initiated to add new independent directors with complementary healthcare, clinical, and value-based care expertise.

“On behalf of the Board of Directors, I want to thank Gabe for his service during an important chapter in The Oncology Institute’s development,” said Anne McGeorge, Chairman of the Board. “We appreciate the contributions he made throughout his time on the Board and the valuable guidance he provided as the Company navigated its first few years in the public markets. As we continue to strengthen our governance structure, we remain focused on enhancing the Board’s capabilities by bringing on strategic and experienced members who will support The Oncology Institute’s mission and long-term growth goals.”

About The Oncology Institute
Founded in 2007, The Oncology Institute (NASDAQ: TOI) is advancing oncology by delivering highly specialized, value-based cancer care in the community setting. TOI offers cutting-edge, evidence-based cancer care to a population of approximately 1.9 million patients, including clinical trials, transfusions, and other care delivery models traditionally associated with the most advanced care delivery organizations. With over 180 employed and affiliate clinicians and over 100 clinics and affiliate locations of care across five states and growing, TOI is changing oncology for the better. For more information, visit www.theoncologyinstitute.com

Contacts

Media

The Oncology Institute, Inc.
marketing@theoncologyinstitute.com

Investors

ICR Healthcare
TOI@icrhealthcare.com

Release – InPlay Oil Corp. Confirms Monthly Dividend for December 2025

Posted on by aweinsoff@channelchek.com

Research News and Market Data on IPOOF

InPlay Oil Corp. 

Dec 01, 2025, 07:30 ET

CALGARY, AB, Dec. 1, 2025 /CNW/ – InPlay Oil Corp. (TSX: IPO) (OTCQX: IPOOF) (“InPlay” or the “Company”) is pleased to confirm that its Board of Directors has declared a monthly cash dividend of $0.09 per common share payable on December 31, 2025, to shareholders of record at the close of business on December 15, 2025.  The monthly cash dividend is expected to be designated as an “eligible dividend” for Canadian federal and provincial income tax purposes.

About InPlay Oil Corp.

InPlay is a junior oil and gas exploration and production company with operations in Alberta focused on light oil production. The company operates long-lived, low-decline properties with drilling development and enhanced oil recovery potential as well as undeveloped lands with exploration possibilities. The common shares of InPlay trade on the Toronto Stock Exchange under the symbol IPO and the OTCQX Exchange under the symbol IPOOF.

www.inplayoil.com

SOURCE InPlay Oil Corp.

For further information please contact: Doug Bartole, President and Chief Executive Officer, InPlay Oil Corp., Telephone: (587) 955-0632; Darren Dittmer, Chief Financial Officer, InPlay Oil Corp., Telephone: (587) 955-0634

Release – V2X to Modernize and Upgrade F-16 Cockpits Under $425 Million Award

Posted on by aweinsoff@channelchek.com
V2X (PRNewsfoto/V2X, Inc.)

Research News and Market Data on VVX

December 01, 2025

RESTON, Va., Dec. 1, 2025 /PRNewswire/ — V2X, Inc. (NYSE: VVX), announced it has been awarded a 10-year, $425 million indefinite-delivery, indefinite-quantity contract to modernize and upgrade cockpit displays for the U.S. Air Force F-16 fleet.

Under the contract, V2X will provide center display units (CDU’s) full kits, line-replaceable units, shop-replaceable units, and related support hardware for the combat jet.

“This is a great example of how smart modernization can deliver immediate mission enhancement,” said Jeremy C. Wensinger, President and Chief Executive Officer at V2X. “By upgrading the F-16 cockpit display at a significantly lower cost than full replacement, we are strengthening the digital backbone of the aircraft and enhancing operational effectiveness for decades to come.”

The award builds on past orders and represents the largest award we have received for the F-16 CDU program. V2X’s approach to cockpit modernization delivers cost-effective technology insertion with minimal retrofit, ensuring enhanced combat effectiveness while reducing overall lifecycle costs.

Work will be performed at V2X’s facility in Indianapolis, Indiana, and is expected to be completed by September 2035.

About V2X
V2X builds innovative solutions that integrate physical and digital environments by aligning people, actions, and technology. V2X is embedded in all elements of a critical mission’s lifecycle to enhance readiness, optimize resource management, and boost security. The company provides innovation spanning national security, defense, civilian, and international markets. With a global team of approximately 16,000 professionals, V2X enables mission success by injecting AI and machine learning capabilities to meet today’s toughest challenges across all operational domains.

Media Contact
Angelica Spanos Deoudes
Director, Corporate Communications
Angelica.Deoudes@goV2X.com
571-338-5195

Investor Contact
Mike Smith, CFA
Vice President, Treasury, Corporate Development and Investor Relations
IR@goV2X.com
719-637-5773

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/v2x-to-modernize-and-upgrade-f-16-cockpits-under-425-million-award-302628182.html

SOURCE V2X, Inc.

Gold and Silver Surge as Crypto Selloff Fuels Flight to Safety

Posted on by slightbourne@noblecapitalmarkets.com

Gold and silver prices climbed sharply on Monday as investors sought out safer assets amid growing expectations of a Federal Reserve rate cut in December and rising concern over currency volatility triggered by a surging Japanese yen. The combination of shifting monetary policy, weakening crypto markets, and broader uncertainty across global assets helped propel precious metals to new milestones.

Gold futures pushed above $4,270 per troy ounce, extending the metal’s winning streak to a fourth consecutive month. The latest rally puts gold less than 2% away from its October all-time high of $4,336. With more than a 60% gain year-to-date, gold has vastly outperformed major stock indices like the S&P 500 and has moved ahead of bitcoin, which is now down roughly 9% for the year after Monday’s steep drop.

Silver’s performance has been even more dramatic. The metal briefly surged above $58 per ounce, marking a fresh nominal all-time high. While inflation-adjusted levels remain below the historic 1980 peak near $150, silver’s 100% year-to-date rise reflects strong investor demand, tightening supply, and heightened interest in smaller, more volatile precious metals markets. Many analysts now believe the metal could soon test the $60 level.

A major catalyst behind the rally is increasing confidence that the Federal Reserve may cut interest rates by at least 25 basis points at its upcoming meeting. Softer commentary from Fed officials in recent weeks has strengthened expectations for easing monetary policy, putting downward pressure on the US dollar. A weaker dollar typically supports precious metals, making them more attractive to international investors.

Lower rates also reduce the competitive appeal of yield-bearing assets such as Treasury bonds, prompting investors to reallocate funds into gold and silver, which historically perform better in easing cycles.

Another factor lifting metals on Monday was turbulence in the foreign exchange market. A surge in the Japanese yen raised concerns that investors who previously borrowed cheaply in yen to buy higher-yielding US assets might unwind those positions. Such a shift can destabilize broader markets, driving traders into defensive holdings like bullion.

Meanwhile, cryptocurrency markets saw a sharp pullback, adding momentum to the metals rally. Bitcoin’s decline contributed to a broader move out of speculative digital assets and into traditional safe havens.

While gold attracts the most attention, other precious metals have also benefited from tightening market conditions. Platinum is up more than 85% this year, and palladium has gained over 65%, reflecting their smaller market sizes and heightened sensitivity to supply constraints.

Looking ahead, major banks are projecting further upside for bullion. Goldman Sachs expects gold to approach $4,900 by the end of next year, while UBS recently raised its mid-2026 target to $4,500 per ounce, citing strong demand for portfolio diversification and ongoing geopolitical uncertainty.

As investors continue to navigate a landscape marked by shifting monetary policy, currency disruptions, and volatile risk assets, gold and silver appear well positioned to remain key beneficiaries of the global flight to safety.

Bit Digital (BTBT) – 3Q25 Review and Updated Models

Posted on by slightbourne@noblecapitalmarkets.com


Monday, December 01, 2025

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Review. In the third quarter, Bit Digital continued its transformation into an ETH focused treasury firm. Management continued its orderly wind-down of the bitcoin mining business, while the WhiteFiber holding has significant upside potential, in our view. Management has successfully guided the Company through past periods of volatility, and we believe they will be successful once again.

ETH. ETH prices remain volatile, currently trading just above $3,000, down from the $4,800 level at the end of the summer. However, as the backbone of decentralized finance (DeFi), NFTs (non-fungible tokens), and numerous blockchain-based platforms, industry experts expect the demand for ETH to grow over time, positively impacting the long-term price.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

FAT Brands (FAT) – A Debt Acceleration; Moving to Market Perform

Posted on by slightbourne@noblecapitalmarkets.com


Monday, December 01, 2025

FAT Brands (NASDAQ: FAT) is a leading global franchising company that strategically acquires, markets, and develops fast casual, quick-service, casual dining, and polished casual dining concepts around the world. The Company currently owns 17 restaurant brands: Round Table Pizza, Fatburger, Marble Slab Creamery, Johnny Rockets, Fazoli’s, Twin Peaks, Great American Cookies, Hot Dog on a Stick, Buffalo’s Cafe & Express, Hurricane Grill & Wings, Pretzelmaker, Elevation Burger, Native Grill & Wings, Yalla Mediterranean and Ponderosa and Bonanza Steakhouses, and franchises and owns over 2,300 units worldwide. For more information on FAT Brands, please visit www.fatbrands.com.

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Debt Acceleration. In an 8-K filing, FAT Brands disclosed on November 17, 2025, that the Company received notices of acceleration from UMB with respect to Securitization Notes issued by FAT Brands GFG Royalty I, LLC, FAT Brands Royalty I, LLC, FAT Brands Fazoli’s Native I, LLC, and Twin Hospitality I, LLC. The Acceleration Notices basically state that all amounts outstanding under the Notes are immediately due and payable. FAT Brands does not have the capital to repay all amounts due under the Notes.

Past Negotiations. In a November 14th 8-K filing, FAT Brands reported “cleansing material” related to the negotiations to modify the outstanding debt. In our view, there appears to be significant agreement on many issues, with key differences being the timing of certain items, certain payments to management and/or outside parties, and parties to receive certain reports.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Twin Hospitality (TWNP) – A Debt Acceleration; Moving to Market Perform

Posted on by slightbourne@noblecapitalmarkets.com


Monday, December 01, 2025

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Debt Acceleration. In separate 8-K filings, parent company FAT Brands and Twin Hospitality disclosed on November 17, 2025, the firms received notices of acceleration from UMB with respect to Securitization Notes issued by four of the Securitization Issuers, with Twin Hospitality I, LLC specific to the Company. The Acceleration Notice basically states that all amounts outstanding under the Notes are immediately due and payable. Neither FAT Brands nor Twin Hospitality has the capital to repay the Twin Note.

Balance Sheet. We view the issue to be capital structure related, not operating performance. Twin is showing improvement in operating metrics, especially when factoring in the negative impact of closing Smokey Bones locations for conversion. In 3Q25, the Company expanded Twin Peaks’ profit margins by 72 basis points to 17%. While comparable sales declined, Twin was able to maintain steady system-wide weekly sales averaging $11.3 million over the past 12 weeks.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.